日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Clinical characteristics, outcomes, and subtype diversity in hospitalized human rhinovirus (HRV) patients

住院人鼻病毒（HRV）患者的临床特征、预后和亚型多样性

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0335739
Jurkowicz, Menucha; Solomovich, Michael; Leibovitz, Eugene; Keller, Nathan; Yahav, Dafna; Barkai, Galia; Atari, Nofar; Fratty, Ilana S; Cohen, Hodaya; Belkin, Ana; Lustig, Yaniv; Stein, Michal; Mandelboim, Michal
微生物学
发表日期：2025
文献求助 收藏

Hospital surveillance of respiratory viruses during the COVID-19 pandemic and beyond: contribution to the WHO mosaic framework, Israel, 2020 to 2023

2020年至2023年以色列在COVID-19大流行期间及之后开展的呼吸道病毒医院监测：对世卫组织马赛克框架的贡献

期刊:Eurosurveillance
影响因子:7.8
doi:10.2807/1560-7917.ES.2024.29.32.2300634
Gur-Arie, Lea; Stein, Michal; Sefty, Hanna; Fratty, Ilana S; Nemet, Ital; Kliker, Limor; Atari, Nofar; Zuckerman, Neta S; Rosenberg, Alina; Ivgi, Heftziba; Golan-Shany, Orit; Sorek, Nadav; Schwartz-Harari, Orna; Bromberg, Michal; Keinan-Boker, Lital; Mandelboim, Michal; Glatman-Freedman, Aharona
微生物学
发表日期：2024
文献求助 收藏

Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia

单克隆抗体Tixagevimab-Cilgavimab用于预防慢性淋巴细胞白血病患者感染SARS-CoV-2新出现的耐药变异株的疗效

期刊:Acta Haematologica
影响因子:1.1
doi:10.1159/000537690
Benjamini, Ohad; Tadmor, Tamar; Avigdor, Abraham; Gershon, Rotem; Kliker, Limor; Fares, Florin; Atari, Nofar; Laevsky, Ilana; Abdelkader, Bayan; Hod, Tammy; Golan-Shany, Orit; Mandelboim, Michal; Rahav, Galia
单克隆抗体
SARS-CoV-2
炎症/感染
白血病
细胞生物学
发表日期：2024
文献求助 收藏

Cocirculation of A(H3N2) and B/Victoria increased morbidity in hospitalized patients in the 2019-2020 A(H1N1)pdm09 predominant influenza season in Israel

在以色列2019-2020年A(H1N1)pdm09流感流行季，A(H3N2)和B/Victoria的共同流行增加了住院患者的发病率。

期刊:Journal of Medical Virology
影响因子:4.6
doi:10.1002/jmv.28498
Jurkowicz, Menucha; Nemet, Ital; Atari, Nofar; Fratty, Ilana S; Kliker, Limor; Sherbany, Hilda; Keller, Nathan; Leibovitz, Eugene; Mendelson, Ella; Mandelboim, Michal; Stein, Michal
微生物学
流感
发表日期：2023
文献求助 收藏

Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study.

肿瘤电场治疗（TTFields）在体外表现出抗病毒功能，并在初步临床研究中证明其对 COVID-19 患者安全有效

期刊:Frontiers in Microbiology
影响因子:4.5
doi:10.3389/fmicb.2023.1296558
Abutbul Avraham, Mumblat Helena, Porat Yaara, Friedman Nehemya, Atari Nofar, Sharabi Shirley, Nama Ahmad, Mugahed Waseem, Kessler Asa, Kolben Yotam, Shamir Reuben Ruby, Manzur Doron, Farber Ori, Bosch Liora, Lavy-Shahaf Gitit, Dor-On Eyal, Haber Adi, Giladi Moshe, Weinberg Uri, Palti Yoram, Mardor Yael, Mandelboim Michal
肿瘤
Viral
发表日期：2023
文献求助 收藏

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022-2023 Winter Season

2022-2023年冬季以色列联合接种二价新冠疫苗和四价季节性流感疫苗的免疫原性

期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines11101624
Moss, Stephen; Jurkowicz, Menucha; Nemet, Ital; Atari, Nofar; Kliker, Limor; Abd-Elkader, Bayan; Gonen, Tal; Martin, Emily Toth; Lustig, Yaniv; Regev-Yochay, Gili; Mandelboim, Michal
微生物学
新冠
流感
免疫/内分泌
发表日期：2023
文献求助 收藏

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022

COVID-19 疫苗接种和 BA.1 突破性感染诱导产生的抗体对 BA.4 和 BA.5 Omicron 变种的效力较低。以色列，2022 年 3 月至 6 月

期刊:Eurosurveillance
影响因子:7.8
doi:10.2807/1560-7917.ES.2022.27.30.2200559
Kliker, Limor; Zuckerman, Neta; Atari, Nofar; Barda, Noam; Gilboa, Mayan; Nemet, Ital; Abd Elkader, Bayan; Fratty, Ilana S; Jaber, Hanaa; Mendelson, Ella; Alroy-Preis, Sharon; Kreiss, Yitshak; Regev-Yochay, Gili; Mandelboim, Michal
炎症/感染
发表日期：2022
文献求助 收藏

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022

2022年6月至9月，以色列，接种疫苗的个体在发生BA.1和BA.5突破性感染后，Omicron BA.2.75变体被有效中和。

期刊:Eurosurveillance
影响因子:7.8
doi:10.2807/1560-7917.ES.2022.27.44.2200785
Atari, Nofar; Kliker, Limor; Zuckerman, Neta; Elkader, Bayan Abd; Weiss-Ottolenghi, Yael; Mendelson, Ella; Kreiss, Yitshak; Regev-Yochay, Gili; Mandelboim, Michal
炎症/感染
发表日期：2022
文献求助 收藏

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

以色列医护人员接种Comirnaty（BNT162b2，BioNTech/辉瑞）疫苗后，对Delta（B.1.617.2）及其他关注变异株的中和能力

期刊:Eurosurveillance
影响因子:7.8
doi:10.2807/1560-7917.ES.2021.26.26.2100557
Lustig, Yaniv; Zuckerman, Neta; Nemet, Ital; Atari, Nofar; Kliker, Limor; Regev-Yochay, Gili; Sapir, Einav; Mor, Orna; Alroy-Preis, Sharon; Mendelson, Ella; Mandelboim, Michal
发表日期：2021
文献求助 收藏

The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

2021年4月至6月，以色列，SARS-CoV-2 Lambda变异株及其接种Comirnaty疫苗后的中和效率

期刊:Eurosurveillance
影响因子:7.8
doi:10.2807/1560-7917.ES.2021.26.45.2100974
Zuckerman, Neta; Nemet, Ital; Kliker, Limor; Atari, Nofar; Lustig, Yaniv; Bucris, Efrat; Bar Ilan, Dana; Geva, Miranda; Sorek-Abramovich, Reut; Weiner, Chen; Rainy, Nir; Bar-Chaim, Adina; Benveniste-Levkovitz, Patricia; Abu Hamed, Ramzia; Regev-Yochay, Gili; Hevkin, Ofra; Mor, Orna; Alroy-Preis, Sharon; Mendelson, Ella; Mandelboim, Michal
SARS-CoV-2
发表日期：2021
文献求助 收藏